Company Profile
Seer
Company Overview
Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
Our novel Proteograph™ platform allows for the first-ever generation of proprietary proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, and affording comprehensive insights to deliver first-in-class liquid biopsy products with a goal of achieving very early disease detection.
We are advancing a portfolio of first-in-class liquid biopsy products to detect disease at early, pre-symptomatic stages to drive earlier treatment and improved outcomes. We will also seek to establish strategic collaborations with industry partners to leverage our Proteograph platform to impact drug discovery and development.
https://seer.bio/
Company History
Seer is led by Omid Farokhzad, Chief Executive Officer, who brings more than 20 years of experience in biomedical research and building successful biotechnology companies. Philip Ma serves as Chief Business Officer and President, and brings 23 years of business and scientific leadership, including executive positions at Biogen and McKinsey & Company. Bob Langer is a Director of Seer Biosciences, and an Institute Professor at M.I.T. Dr. Langer is recognized as a serial entrepreneur and an academic luminary, having won over 300 major scientific awards, including the United States National Medal of Science, and the United States National Medal of Technology.
Benefits
An attractive compensation package including stock options, will be offered based upon background and experience.